{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:55:10Z","timestamp":1793836510450,"version":"4.6.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune mediated inflammatory diseases (IMIDs) are a heterogeneous group of debilitating, multifactorial and unrelated conditions featured by a dysregulated immune response leading to destructive chronic inflammation. The immune dysregulation can affect various organ systems: gut (e.g., inflammatory bowel disease), joints (e.g., rheumatoid arthritis), skin (e.g., psoriasis, atopic dermatitis), resulting in significant morbidity, reduced quality of life, increased risk for comorbidities, and premature death. As there are no reliable disease progression and therapy response biomarkers currently available, it is very hard to predict how the disease will develop and which treatments will be effective in a given patient. In addition, a considerable proportion of patients do not respond sufficiently to the treatment. ImmUniverse is a large collaborative consortium of 27 partners funded by the Innovative Medicine Initiative (IMI), which is sponsored by the European Union (Horizon 2020) and in-kind contributions of participating pharmaceutical companies within the European Federation of Pharmaceutical Industries and Associations (EFPIA). ImmUniverse aims to advance our understanding of the molecular mechanisms underlying two immune-mediated diseases, ulcerative colitis (UC) and atopic dermatitis (AD), by pursuing an integrative multi-omics approach. As a consequence of the heterogeneity among IMIDs patients, a comprehensive, evidence-based identification of novel biomarkers is necessary to enable appropriate patient stratification that would account for the inter-individual differences in disease severity, drug efficacy, side effects or prognosis. This would guide clinicians in the management of patients and represent a major step towards personalized medicine. ImmUniverse will combine the existing and novel advanced technologies, including multi-omics, to characterize both the tissue microenvironment and blood. This comprehensive, systems biology-oriented approach will allow for identification and validation of tissue and circulating biomarker signatures as well as mechanistic principles, which will provide information about disease severity and future disease progression. This truly makes the ImmUniverse Consortium an unparalleled approach.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1002629","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T17:03:47Z","timestamp":1668013427000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["ImmUniverse Consortium: Multi-omics integrative approach in personalized medicine for immune-mediated inflammatory diseases"],"prefix":"10.3389","volume":"13","author":[{"given":"Stefania","family":"Vetrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerben","family":"Bouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Benschop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Birngruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. R. A. M.","family":"D\u2019Haens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Frasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Hillenbrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J. P. M.","family":"Koenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Noehammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Raes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Ricotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Rosenstiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata P.","family":"Satagopam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ziemek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ImmUniverse Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00603-1","article-title":"Immune-mediated inflammatory disease therapeutics: past, present and future","volume":"21","author":"McInnes","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1568-9972(03)00006-5","article-title":"The epidemiology of autoimmune diseases","volume":"2","author":"Cooper","year":"2003","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/cei.13158","article-title":"The microbiome in autoimmune diseases","volume":"195","author":"De Luca","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9020353","article-title":"Gut-skin axis: Current knowledge of the interrelationship between microbial dysbiosis and skin conditions","volume":"9","author":"De Pessemier","year":"2021","journal-title":"Microorganisms"},{"key":"B6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: Medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI19836","article-title":"Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis","volume":"113","author":"Fuss","year":"2004","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2008.40","article-title":"The role of IL-13 and NK T cells in experimental and human ulcerative colitis","author":"Fuss","year":"2008","journal-title":"Mucosal Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.03.013","article-title":"Efficient early drug development for ulcerative colitis","volume":"150","author":"Khanna","year":"2016","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/all.13401","article-title":"Epidemiology of atopic dermatitis in adults: Results from an international survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic dermatitis in America study: A cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population","volume":"139","author":"Chiesa Fuxench","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jaip.2018.11.043","article-title":"Health utility scores of atopic dermatitis in US adults","volume":"7","author":"Silverberg","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17203","article-title":"Cost-of-illness of atopic dermatitis in Germany: data from dermatology routine care","volume":"35","author":"Mohr","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18442","article-title":"The cost of childhood atopic dermatitis in a multi-ethnic Asian population: a cost-of-illness study","volume":"182","author":"Olsson","year":"2020","journal-title":"Br J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.10.024","article-title":"Health care resource utilization and costs among adults with atopic dermatitis in the united states: A claims-based analysis","volume":"6","author":"Drucker","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.055","article-title":"Prevalence of asthma in patients with atopic dermatitis: A systematic review and meta-analysis","volume":"84","author":"Ravnborg","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaad.2016.08.047","article-title":"Autoimmune diseases in adults with atopic dermatitis","volume":"76","author":"Andersen","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaad.2018.03.017","article-title":"Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis","volume":"79","author":"Ronnstad","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14446","article-title":"The power and potential of BIOMAP to elucidate host-microbiome interplay in skin inflammatory diseases","volume":"30","author":"Alenius","year":"2021","journal-title":"Exp Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","article-title":"Multi-omics approaches to disease","volume":"18","author":"Hasin","year":"2017","journal-title":"Genome Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02727","article-title":"Leveraging multilayered \"Omics\" data for atopic dermatitis: A road map to precision medicine","volume":"9","author":"Ghosh","year":"2018","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2019.0373","article-title":"Systems biology in inflammatory bowel diseases: on the way to precision medicine","volume":"32","author":"Dovrolis","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000367836","article-title":"Integrating omics: the future of IBD","author":"Fiocchi","year":"2014","journal-title":"Dig Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.07.034","article-title":"Multi-center harmonization of flow cytometers in the context of the European \"PRECISESADS\" project","volume":"15","author":"Jamin","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217116","article-title":"Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients","volume":"79","author":"Beretta","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1038\/s41467-021-23472-7","article-title":"A new molecular classification to drive precision treatment strategies in primary sjogren's syndrome","volume":"12","author":"Soret","year":"2021","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","first-page":"102524","DOI":"10.1016\/j.jaut.2020.102524","article-title":"Antiphospholipid autoantibody detection is important in all patients with systemic autoimmune diseases","volume":"115","author":"Marziale","year":"2020","journal-title":"J Autoimmun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/art.41697","article-title":"A proinflammatory cytokine network profile in Th1\/Type 1 effector b cells delineates a common group of patients in four systemic autoimmune diseases","volume":"73","author":"Simon","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"100090","DOI":"10.1016\/j.jtauto.2021.100090","article-title":"An elevated polyclonal free light chain level reflects a strong interferon signature in patients with systemic autoimmune diseases","volume":"4","author":"Bettacchioli","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2014.08.014","article-title":"The integrative human microbiome project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease","volume":"16","year":"2014","journal-title":"Cell Host Microbe"},{"key":"B39","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/gb-2012-13-9-r79","article-title":"Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment","volume":"13","author":"Morgan","year":"2012","journal-title":"Genome Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2014.02.005","article-title":"The treatment-naive microbiome in new-onset crohn's disease","volume":"15","author":"Gevers","year":"2014","journal-title":"Cell Host Microbe"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75436","article-title":"Pediatric crohn disease patients exhibit specific ileal transcriptome and microbiome signature","volume":"124","author":"Haberman","year":"2014","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12876-019-0938-8","article-title":"Correction to: The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1","volume":"19","author":"Imhann","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20587","article-title":"The BIOMarkers in atopic dermatitis and psoriasis (BIOMAP) glossary: developing a lingua franca to facilitate data harmonization and cross-cohort analyses","volume":"185","author":"Broderick","year":"2021","journal-title":"Br J Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11095-020-02962-1","article-title":"Evaluating dermal pharmacokinetics and pharmacodymanic effect of soft topical PDE4 inhibitors: Open flow microperfusion and skin biopsies","volume":"37","author":"Eirefelt","year":"2020","journal-title":"Pharm Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"121737","DOI":"10.1016\/j.ijpharm.2022.121737","article-title":"Optimization of topical formulations using a combination of in vitro methods to quantify the transdermal passive diffusion of drugs","volume":"620","author":"Hummer","year":"2022","journal-title":"Int J Pharm"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0442-z","article-title":"Open flow microperfusion as a dermal pharmacokinetic approach to evaluate topical bioequivalence","volume":"56","author":"Bodenlenz","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"Beta-defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1002629\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T17:03:51Z","timestamp":1668013431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1002629\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2022.1002629"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1002629","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"article-number":"1002629"}}